Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer

BJU International

Volumn 110, Issue 11, 2012, Pages 1672-1677

  Bul, Meelan ^a   Van Den Bergh, Roderick C N ^a   Zhu, Xiaoye ^a   Rannikko, Antti ^b   Vasarainen, Hanna ^b   Bangma, Chris H ^a   Schröder, Fritz H ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

active surveillance; disease progression; early detection of cancer; prostatic neoplasms; survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL; SURVIVAL RATE; THERAPY DELAY; TREATMENT FREE SURVIVAL;

EID: 84870898032     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11434.x     Document Type: Article

References (23)

1. Hernandez J, Thompson IM,. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004; 101: 894-904
2. Draisma G, Boer R, Otto SJ, et al,. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78
3. Parker C,. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004; 5: 101-6
4. van den Bergh RC, Vasarainen H, van der Poel HG, et al,. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: active Surveillance' study. BJU Int 2010; 105: 956-62
5. Roobol MJ, Kirkels WJ, Schroder FH,. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int 2003; 92: 48-54
6. Finne P, Stenman UH, Maattanen L, et al,. The Finnish trial of prostate cancer screening: where are we now? BJU Int 2003; 92: 22-6
7. van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH,. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 2007; 52: 1560-3
8. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509
9. Stattin P, Holmberg E, Johansson JE, et al,. Outcomes in localized prostate cancer: national Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010; 102: 950-8
10. Lu-Yao GL, Albertsen PC, Moore DF, et al,. Outcomes of localized prostate cancer following conservative management. JAMA 2009; 302: 1202-9
11. Bill-Axelson A, Holmberg L, Filen F, et al,. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group 4 randomized trial. J Natl Cancer Inst 2008; 100: 1144-54
12. Bill-Axelson A, Holmberg L, Ruutu M, et al,. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364: 1708-17
13. Wilt TJ, Brawer MK, Jones KM, et al,. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203-13
14. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A,. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-31
15. Cooperberg MR, Cowan JE, Hilton JF, et al,. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2011; 29: 228-34
16. Tosoian JJ, Trock BJ, Landis P, et al,. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 2185-90
17. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M,. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 2010; 58: 831-5
18. van As NJ, Norman AR, Thomas K, et al,. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008; 54: 1297-305
19. Bul M, van den Bergh RC, Rannikko A, et al,. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. Eur Urol 2012; 61: 370-7
20. Hayes JH, Ollendorf DA, Pearson SD, et al,. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010; 304: 2373-80
21. van den Bergh RC, Essink-Bot ML, Roobol MJ, et al,. Anxiety and distress during active surveillance for early prostate cancer. Cancer 2009; 115: 3868-78
22. Albertsen PC, Hanley JA, Barrows GH, et al,. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97: 1248-53
23. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Committee IG,. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-42